Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + CAPOX + short-course radiotherapy as total neoadjuvant therapy for locally advanced rectal cancer
ChiCTR2500104302Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in rectal adenocarcinoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: pathological complete response rate. Started Jun 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500104302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104302.